Abstract
This study explores the effects of different treatment durations of Ruxolitinib on inhibiting JAK phosphorylation of STAT1 in A549 lung cancer cells. The JAK/STAT signaling pathway is critical in lung cancer development and progression. By utilizing western blotting, a STAT luciferase reporter assay, and an MTT viability assay, the study evaluates the impact of Ruxolitinib treatment on STAT1 phosphorylation, STAT activation, and cell viability. Understanding how treatment duration influences JAK/STAT pathway inhibition provides valuable insights for developing targeted therapies in lung cancer. This research contributes to addressing the challenges of lung cancer treatment by exploring the potential of Ruxolitinib as a therapeutic agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
